Twist Acquires Genome Compiler

Twist Bioscience intends to leverage Genome Compiler’s technology and expertise to drive a digital products portfolio, including an eCommerce solution with gene design capabilities, expected to be available in the second half of 2016.

“Twist’s beta program is progressing well and our first customer shipments are underway,” said Emily M. Leproust, Ph.D., CEO of Twist Bioscience. “Over the next few months we expect to scale our gene volume substantially, enabling us to offer market-leading production levels by this summer. We are delighted to bring the Genome Compiler technology, network and expert team into the Twist Bioscience organization. They are the leader in developing software that allows design of gene sequences for synthetic and molecular biology experiments. We intend to build an elegant, intuitive eCommerce solution with a deep pipeline of digital products to follow that will enable our customers to reimagine their research by providing seamless integration of the design and build of their synthetic DNA.”

Under the terms of the agreement, the Genome Compiler research and development center in Israel will become Twist Bioscience’s first international site. Twist Bioscience intends to expand the center in Tel Aviv to advance its digital product and gene design capabilities.  Financial terms of the deal were not disclosed.

“We are extremely excited to join forces with Twist Bioscience,” commented Omri Amirav-Drory, Ph.D., founder and CEO of Genome Compiler.  “By combining our advanced software design capabilities with the technology leader in DNA synthesis, our customers will be able to streamline the design-build-test cycle. We believe the synthetic and molecular biology communities will find the integrated offering a great platform to accelerate their research.”